Vertex Announces Leadership Transition and Reports Q4 2024 Financial Results

Details

Arbuckle, effective July 1, 2025. Charles F. Wagner, Jr. will assume the role of Chief Operating Officer and continue as Chief Financial Officer. Duncan J. McKechnie will join as Chief Commercial Officer. Vertex reported consolidated financial results for Q4 and full year 2024, with full-year product revenue of $11.02 billion. The company provided full-year 2025 financial guidance, expecting total revenue between $11.75 billion to $12.0 billion.

Items reported

Exhibits (1)

About Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Inc. is a leading biotechnology company focused on the discovery, development, and commercialization of innovative therapies for serious diseases. Primarily, Vertex is known for its pioneering work in treating cystic fibrosis (CF), a genetic disorder that affects respiratory and digestive systems. Through its robust portfolio of CF-focused therapies, Vertex addresses a significant unmet medical need, improving the quality of life for patients worldwide. The company's research pipeline also includes promising treatments for other serious conditions, including sickle cell disease and beta thalassemia. Based in Boston, Massachusetts, Vertex Pharmaceuticals serves the global healthcare sector, collaborating with key industry players and academic institutions to advance its scientific initiatives. Its role in the biotechnology landscape is significant, both for its impact on patient outcomes and its contribution to advancing medical science through innovation and targeted therapeutic solutions.